Related Experiment Videos
Hepatorenal Syndrome
1Liver Section, Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet, 08916 Badalona, Spain.
Insights
Hepatorenal syndrome (HRS) management is challenging. Treatments like terlipressin and TIPS show promise for improving kidney function and survival, serving as potential bridges to liver transplantation or alternatives for non-transplant candidates.
Area of Science:
- Hepatology
- Nephrology
- Transplantation
Background:
- Hepatorenal syndrome (HRS) is a severe complication of advanced liver disease with poor prognosis.
- Orthotopic liver transplantation (OLT) is the only definitive treatment for HRS, but it is not universally applicable.
- Many patients with HRS have a high mortality rate while awaiting OLT due to prolonged waiting lists.
Purpose of the Study:
- To review current challenges in HRS management.
- To explore potential therapeutic strategies for HRS beyond OLT.
- To highlight the need for effective treatments that improve renal function and survival in HRS patients.
Main Methods:
- Review of preliminary studies on splanchnic vasoconstrictors (e.g., terlipressin) and volume expanders.
- Evaluation of transjugular intrahepatic portosystemic shunts (TIPS) as a treatment modality for HRS.
- Discussion of the role of these therapies as a bridge to OLT or as an alternative for non-transplant candidates.
Main Results:
- Preliminary data suggest that terlipressin combined with volume expansion may improve renal function in HRS.
- TIPS insertion has also shown potential in improving renal outcomes for patients with HRS.
- Further research is required to validate these findings and establish definitive treatment guidelines.
Conclusions:
- Effective therapies for HRS are needed to improve renal function and patient survival.
- Splanchnic vasoconstrictors and TIPS are promising therapeutic options for HRS.
- Additional clinical studies are necessary before widespread recommendation of these treatments for hepatorenal syndrome.
Abstract:
The management of the hepatorenal syndrome (HRS) constitutes a major challenge for clinicians. Because HRS is a functional disorder due to advanced liver disease and is associated with a very low survival expectancy, orthotopic liver transplantation (OLT) is the only effective and permanent treatment for patients with HRS. However, OLT is not applicable to all cirrhotic patients despite the presence of HRS. In addition, because of the poor prognosis of HRS and the prolonged waiting lists in most transplant centers a significant proportion of these patients may die before OLT is possible. Therefore, there is a need for effective therapies for HRS that improve renal function and increase survival. Such treatments are of interest not only as a bridge to OLT but also as a therapy for patients who are not candidates for transplantation. Preliminary studies have suggested that the administration of splanchnic vasoconstrictors such as terlipressin in combination with volume expanders or the insertion of transjugular intrahepatic portosystemic shunts (TIPS) may improve renal function in patients with HRS. However, before these treatments are widely recommended further studies are necessary.